{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:18:46Z","timestamp":1790709526570,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004946","name":"National Chung-Hsing University","doi-asserted-by":"publisher","award":["NCHU-CSMU11313"],"award-info":[{"award-number":["NCHU-CSMU11313"]}],"id":[{"id":"10.13039\/501100004946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-109-2320-B-040-009"],"award-info":[{"award-number":["NSTC-109-2320-B-040-009"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-112-2320-B-005-014-MY3"],"award-info":[{"award-number":["NSTC-112-2320-B-005-014-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04335-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:16:19Z","timestamp":1772442979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dasatinib boosts \u03b3\u03b4 T cell expansion and memory phenotypes with enhanced antitumor immunity"],"prefix":"10.1007","volume":"75","author":[{"given":"Jeng-Rong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying\u2010Chyi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Lun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Pi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chieh","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Rong","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"4335_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B (2024) Cancer immunotherapy by gammadelta T cells. Science 386:eabq7248","journal-title":"Science"},{"key":"4335_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z et al (2023) Gammadelta T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther 8:434","journal-title":"Signal Transduct Target Ther"},{"key":"4335_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","volume":"613","author":"NL de Vries","year":"2023","unstructured":"de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M et al (2023) gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613:743\u2013750","journal-title":"Nature"},{"key":"4335_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/cmi.2012.45","volume":"10","author":"WK Born","year":"2013","unstructured":"Born WK, Kemal Aydintug M, O\u2019Brien RL (2013) Diversity of gammadelta T-cell antigens. Cell Mol Immunol 10:13\u201320","journal-title":"Cell Mol Immunol"},{"key":"4335_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889051","author":"RY Dong","year":"2022","unstructured":"Dong RY, Zhang YX, Xiao HW, Zeng X (2022) Engineering \u03b3\u03b4 T cells: recognizing and activating on their own way. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.889051","journal-title":"Front Immunol"},{"key":"4335_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41423-025-01269-8","volume":"22","author":"D Kabelitz","year":"2025","unstructured":"Kabelitz D, Bhat J (2025) \u03b3\u03b4 T cells as sensors of ectopically expressed intracellular proteins. Cell Mol Immunol 22:456\u2013458","journal-title":"Cell Mol Immunol"},{"key":"4335_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ni.2713","volume":"14","author":"AP Uldrich","year":"2013","unstructured":"Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT et al (2013) CD1d-lipid antigen recognition by the \u03b3\u03b4 TCR. Nat Immunol 14:1137-U125","journal-title":"Nat Immunol"},{"key":"4335_CR8","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1073\/pnas.1015433108","volume":"108","author":"B Xu","year":"2011","unstructured":"Xu B, Pizarro JC, Holmes MA, McBeth C, Groh V, Spies T et al (2011) Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci U S A 108:2414\u20139","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4335_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T cells. Science 309:264\u20138","journal-title":"Science"},{"key":"4335_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/CJI.0b013e31819b7c30","volume":"32","author":"S Landmeier","year":"2009","unstructured":"Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A et al (2009) Activated human \u03b3\u03b4 T cells as stimulators of specific CD8 T-cell responses to subdominant Epstein Barr virus epitopes. J Immunother 32:310\u201321","journal-title":"J Immunother"},{"key":"4335_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann V, Bauer E, Wilhelm M (1999) Gamma\/delta T-cell stimulation by pamidronate. N Engl J Med 340:737\u20138","journal-title":"N Engl J Med"},{"key":"4335_CR12","doi-asserted-by":"publisher","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","volume":"114","author":"S Gu","year":"2017","unstructured":"Gu S, Sachleben JR, Boughter CT, Nawrocka WI, Borowska MT, Tarrasch JT et al (2017) Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vgamma9Vdelta2 T cell activation. Proc Natl Acad Sci U S A 114:E7311\u2013E20","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4335_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109359","volume":"36","author":"CE Cano","year":"2021","unstructured":"Cano CE, Pasero C, De Gassart A, Kerneur C, Gabriac M, Fullana M et al (2021) BTN2A1, an immune checkpoint targeting Vgamma9Vdelta2 T cell cytotoxicity against malignant cells. Cell Rep 36:109359","journal-title":"Cell Rep"},{"issue":"6","key":"4335_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/cells9061433","volume":"9","author":"T Herrmann","year":"2020","unstructured":"Herrmann T, Fichtner AS, Karunakaran MM (2020) An update on the molecular basis of phosphoantigen recognition by Vgamma9Vdelta2 T cells. Cell 9(6):1433","journal-title":"Cell"},{"key":"4335_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S (2020) Cancer immunotherapy with gammadelta T cells: many paths ahead of us. Cell Mol Immunol 17:925\u201339","journal-title":"Cell Mol Immunol"},{"key":"4335_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00800","volume":"9","author":"T Hoeres","year":"2018","unstructured":"Hoeres T, Smetak M, Pretscher D, Wilhelm M (2018) Improving the efficiency of Vgamma9Vdelta2 T-cell immunotherapy in cancer. Front Immunol 9:800","journal-title":"Front Immunol"},{"key":"4335_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486\u201399","journal-title":"Nat Rev Immunol"},{"key":"4335_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41591-021-01248-2","volume":"27","author":"JA Fraietta","year":"2021","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S et al (2021) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (vol 24, pg 563, 2018). Nat Med 27:561","journal-title":"Nat Med"},{"key":"4335_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z et al (2019) c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576:293","journal-title":"Nature"},{"key":"4335_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673\u201383","journal-title":"Nat Rev Drug Discov"},{"key":"4335_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167\u201374","journal-title":"Cytometry A"},{"key":"4335_CR22","doi-asserted-by":"publisher","first-page":"14378","DOI":"10.1073\/pnas.1611098113","volume":"113","author":"PL Ryan","year":"2016","unstructured":"Ryan PL, Sumaria N, Holland CJ, Bradford CM, Izotova N, Grandjean CL et al (2016) Heterogeneous yet stable Vdelta2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A 113:14378\u201383","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4335_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002274","author":"L Ou","year":"2021","unstructured":"Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L et al (2021) Dichotomous and stable gamma delta T-cell number and function in healthy individuals. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-002274","journal-title":"J Immunother Cancer"},{"key":"4335_CR24","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al (2008) Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111:1366\u201377","journal-title":"Blood"},{"key":"4335_CR25","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK et al (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 14:2484\u201391","journal-title":"Clin Cancer Res"},{"key":"4335_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/leu.2010.11","volume":"24","author":"KC Lee","year":"2010","unstructured":"Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ (2010) Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 24:896\u2013900","journal-title":"Leukemia"},{"key":"4335_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1492","volume":"13","author":"IA Revesz","year":"2024","unstructured":"Revesz IA, Joyce P, Ebert LM, Prestidge CA (2024) Effective gammadelta T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. Clin Transl Immunol 13:e1492","journal-title":"Clin Transl Immunol"},{"key":"4335_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bjc.2011.293","volume":"105","author":"AJ Nicol","year":"2011","unstructured":"Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K et al (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778\u201386","journal-title":"Br J Cancer"},{"key":"4335_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100675","volume":"44","author":"JE Megias-Vericat","year":"2020","unstructured":"Megias-Vericat JE, Ballesta-Lopez O, Barragan E, Martinez-Cuadron D, Montesinos P (2020) Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control? Blood Rev 44:100675","journal-title":"Blood Rev"},{"key":"4335_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garcia-Gutierrez V, Hernandez-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 9:603","journal-title":"Front Oncol"},{"key":"4335_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143429","author":"S Fernandez","year":"2019","unstructured":"Fernandez S, Desplat V, Villacreces A, Guitart AV, Milpied N, Pigneux A et al (2019) Targeting tyrosine kinases in acute myeloid leukemia: why, who and how? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20143429","journal-title":"Int J Mol Sci"},{"key":"4335_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1046771","author":"LJ Liang","year":"2023","unstructured":"Liang LJ, Wang XY, Huang SY, Chen YW, Zhang P, Li L et al (2023) Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1046771","journal-title":"Front Immunol"},{"key":"4335_CR33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F et al (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398\u2013405","journal-title":"Leukemia"},{"key":"4335_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00572-7","author":"YC Chang","year":"2021","unstructured":"Chang YC, Chiang YH, Hsu KT, Chuang CK, Kao CW, Chang YF et al (2021) Activated naive \u03b3\u03b4 T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-021-00572-7","journal-title":"Blood Cancer J"},{"key":"4335_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","volume":"5","author":"C Hekim","year":"2017","unstructured":"Hekim C, Ilander M, Yan J, Michaud E, Smykla R, V\u00e4h\u00e4-Koskela M et al (2017) Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. Cancer Immunol Res 5:157\u201369","journal-title":"Cancer Immunol Res"},{"key":"4335_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-021-00572-7","volume":"11","author":"YC Chang","year":"2021","unstructured":"Chang YC, Chiang YH, Hsu K, Chuang CK, Kao CW, Chang YF et al (2021) Activated naive gammadelta T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer J 11:182","journal-title":"Blood Cancer J"},{"key":"4335_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T et al (2019) The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","journal-title":"Sci Transl Med"},{"key":"4335_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL (2019) Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv 3:711\u20137","journal-title":"Blood Adv"},{"key":"4335_CR39","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","volume":"24","author":"M Xu","year":"2018","unstructured":"Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM et al (2018) Senolytics improve physical function and increase lifespan in old age. Nat Med 24:1246\u201356","journal-title":"Nat Med"},{"key":"4335_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","volume":"21","author":"JL Kirkland","year":"2017","unstructured":"Kirkland JL, Tchkonia T (2017) Cellular senescence: a translational perspective. EBioMedicine 21:21\u20138","journal-title":"EBioMedicine"},{"key":"4335_CR41","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong YM et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539\u201349","journal-title":"Blood"},{"key":"4335_CR42","first-page":"1271","volume":"134","author":"I de Weerdt","year":"2019","unstructured":"de Weerdt I, Hofland T, Lameris R (2019) Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib (vol 132, pg 2260, 2018). Blood 134:1271\u20132","journal-title":"Blood"},{"key":"4335_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM et al (2016) Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127:1117\u201327","journal-title":"Blood"},{"key":"4335_CR44","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1139253","volume":"316","author":"A Rodriguez","year":"2007","unstructured":"Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al (2007) Requirement of bic\/microRNA-155 for normal immune function. Science 316:608\u201311","journal-title":"Science"},{"key":"4335_CR45","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2012.12.006","volume":"38","author":"JC Dudda","year":"2013","unstructured":"Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E et al (2013) MicroRNA-155 is required for effector CD8 T cell responses to virus infection and cancer. Immunity 38:742\u201353","journal-title":"Immunity"},{"key":"4335_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ni.2576","volume":"14","author":"DT Gracias","year":"2013","unstructured":"Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J et al (2013) The microRNA miR-155 controls CD8 T cell responses by regulating interferon signaling. Nat Immunol 14:593","journal-title":"Nat Immunol"},{"key":"4335_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.immuni.2008.11.010","volume":"30","author":"LF Lu","year":"2009","unstructured":"Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K et al (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80\u201391","journal-title":"Immunity"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04335-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:08:31Z","timestamp":1772446111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04335-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4335"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04335-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committees of China Medical University Hospital, Taiwan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"91"}}